LncRNA in the Development of Prostatic Cancer

Prostate cancer (PCa) is among the most frequent cancers in men with an estimated prevalence of 191,930 and 33,330 deaths in the United States in 2020. Recently, the prevalence of PCa in China has rapidly increased annually. The usage of prostate-specific antigen (PSA) has greatly helped us to distinguish PCa. However, PSA has a serious drawback whereas its lack of specificity often results in overdiagnosis. This results in numerous unnecessary recurrent prostate biopsies, with the linked risks and over-treatment of clinically inconsiderable cancers. Although the current treatments for local PCa have improved survival rate, including surgical prostatectomy, chemotherapy, androgen deprivation therapy (ADT), immune therapy, and radiation therapy, severe side events remain. In contrast, advanced prostate cancer has remained an incurable disease. Therefore, developing diagnostic, therapeutic, and prognostic hallmarks is a priority.

This Research Topic aims to investigate the molecular mechanisms underlying the progression and occurrence of non-coding RNAs in Prostate cancer. Firstly, the expression levels in non-coding RNAs in clinical samples and cell lines can be predicted. Secondly, the role of non-coding RNA in Prostate cancer progression can be assessed by functional assays after validation. It can provide new insights into the function of non-coding RNA in Prostate cancer development and it is becoming a molecular diagnosis and therapy.

This Research Topic is the role of non-coding RNA in Prostate cancer progression. Original content detailing the molecular mechanisms of action of long-stranded non-coding RNAs (LncRNAs) in Prostate cancer progression will be of greater interest. We welcome Original Research and Review articles on the following aspects (Submissions may focus on, but are not limited to following subtopics):

1.Effect of non-coding RNAs in the development and progression of urologic malignancies.

2.The role of non-coding RNAs in genitourinary tumorigenesis and development.

3.Application of non-coding RNAs in the treatment of Genitourinary Diseases.

Keywords: Prostatic cancer, Targeting therapy, Non-coding RNA, molecular mechanism

Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.